A flurry of mergers in the healthcare sector appears poised to continue, as Bausch & Lomb is said to be ready to sell itself to Valeant Pharmaceuticals of Canada for about $9 billion. A deal could be announced as soon as Tuesday, people briefed on the matter said, though they said that talks were continuing and could still collapse.
Bausch & Lomb said to be near $9 billion sale to Valeant
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.